Regen BioPharma Inc (RGBP)

[aheadofthecurve]

From otc market website regarding onph mentioning rgbp.
2. Current status as a non-shell company: I am of the opinion that ONPH is not currently a
shell company based upon the following:
a. The 2022 Annual Reports reveal that ONPH is engaged in the business of licensing,
developing, manufacturing and commercializing therapeutics.
b. ONPH, per an agreement with Sybleu Therapeutics, has been granted an exclusive world?wide license to develop its cancer therapy. ONPH has also been granted a license by
NanoSmart Pharmaceuticals Inc. for its "novel" drug delivery platform targeting many
types of cancer and other diseases. ONPH has also been granted a license by KCL
Therapeutics Inc., a wholly owned subsidiary of Regen Biopharma to develop a treatment
for human colon cancer; and a license with Ribera Solutions to develop its clinical trial
patient retention app.
c. ONPH is currently engaged in an active trade or business.
d. For the fiscal year ended March 31, 2022 Annual report, cash constitutes less than 2.5%
of total assets.
e. For the fiscal year ended March 31, 2022, ONPH reported operating expenses (exclusive
of depreciation expense) of $61,201.00. ONPH also made investments in licensing
agreements with NanoSmart Pharmaceuticals for $351,350, KCL Therapeutics for
$1,400,000; Regen Biopharma $55,000; and Ribera Solutions $75,000. These operations
and investments demonstrate greater than nominal operations for a company in this stage
of development. The financial statements of ONPH are consistent with an operating
business.